Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Top Cited Papers
- 17 November 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 21 (2), 181-192
- https://doi.org/10.1016/s1473-3099(20)30843-4
Abstract
No abstract availableKeywords
Funding Information
- Beijing Municipal Science and Technology Commission
- Ministry of Science and Technology of the People's Republic of China
This publication has 23 references indexed in Scilit:
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2Emerging Infectious Diseases, 2020
- A strategic approach to COVID-19 vaccine R&DScience, 2020
- Rapid COVID-19 vaccine developmentScience, 2020
- The race for coronavirus vaccines: a graphical guideNature, 2020
- Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2Emerging Microbes & Infections, 2020
- Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trialClinical Microbiology & Infection, 2019
- Persistence of Antibodies against Middle East Respiratory Syndrome CoronavirusEmerging Infectious Diseases, 2016
- Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trialVaccine, 2012
- Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infectionJournal of Medical Microbiology, 2004